SOURCE: TomoTherapy


August 19, 2010 08:00 ET

TomoTherapy Co-Founder and Chairman Rock Mackie to Be Honored at ESTRO 29 in Barcelona, September 12-16

Mackie to Address Role of Imaging in the Future of Cancer Care in September 13 Lecture

MADISON, WI--(Marketwire - August 19, 2010) - TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced radiation therapy solutions for cancer care, announced today that its Co-Founder and Chairman of the Board, Thomas Rockwell "Rock" Mackie, Ph.D., will be awarded honorary membership into the European Society for Therapeutic Radiology and Oncology (ESTRO) at ESTRO 29, the organization's bi-annual meeting, September 12-16, 2010 in Barcelona.

In addition to being honored for his scientific contributions to the field of radiation oncology, Dr. Mackie also will speak at the conference on September 13, 2010. Dr. Mackie's lecture -- titled "Can closing the visualization gap make cancer a chronic disease?" -- will address how the integration of low dose, quantitative daily imaging into the radiation therapy treatment process can open opportunities for more aggressive, targeted and personalized approaches to cancer care.

Dr. Mackie's lecture is part of a comprehensive scientific program created by ESTRO for its 29th bi-annual meeting. The program has been designed to offer the most relevant and cutting edge science and education in radiation oncology, radiation biology and radiation physics. With a focus on clinical trials, new technology and its clinical implementation, the conference is designed to promote interdisciplinary collaboration.

"I am very proud and humbled to be awarded an honorary membership to ESTRO, an organization committed to helping its members assess and understand new technologies through the lens of patient benefit," said Dr. Mackie. "I look forward to attending the 29th bi-annual meeting in Barcelona, and to presenting my thoughts on the role of integrated imaging in modern radiation therapy."

About TomoTherapy Incorporated 
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy's suite of solutions include its flagship Hi·Art® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy's stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit

©2010 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoDirect, TQA, the TomoTherapy logo and Hi·Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.

Contact Information

  • Investor Contact:
    Thomas E. Powell
    Chief Financial Officer
    Email Contact

    Media Contacts:
    Kevin O'Malley
    Manager, Corporate Communications
    Email Contact

    Susan Lehman
    Rockpoint Public Relations
    Email Contact